Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe.
M de GraafSherief Rahit JanmohamedM L A SchuttelaarTove AgnerJ H AlfonsoS De SchepperM DeleuranK DespontinV EleniusP-D GhislainLaura HuilajaE K JohanssonB K KvenshagenJ M MandelinH OlsetÅke SvenssonA M van Tuyll van SerooskerkenJacob Pontoppidan ThyssenChristian L VestergaardPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
This article makes practical recommendations on the use of systemic AD treatments for children and adolescents, to supplement international and regional guidelines. It considers the systemic medication that was available for children and adolescents with moderate-to-severe AD at the time this consensus project was done: azathioprine, cyclosporine A, dupilumab, methotrexate, mycophenolate mofetil and oral glucocorticosteroids. We focus on the geographically similar Northern European countries, whose healthcare systems, local preferences for AD management and reimbursement structures nonetheless differ significantly.